Skip to main content

Evans John M.'s Form 4 filing

Beam Therapeutics Inc. (BEAM) · filed Nov 2, 2022

Accession no.
0000899243-22-034759
Filed
Nov 2, 2022
Trade date
Oct 31, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions. Open-market sales total $2.32M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Evans John M.CIK 0001786304Director, Officer (CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 31, 2022Common StockSSaleDisposed−7,567$44.92F2−$339,909.641,080,953Direct
Oct 31, 2022Common StockSSaleDisposed−7,768$46.19F3−$358,803.921,073,185Direct
Oct 31, 2022Common StockSSaleDisposed−11,756$46.88F4−$551,121.281,061,429Direct
Oct 31, 2022Common StockSSaleDisposed−2,909$47.89F5−$139,312.011,058,520Direct
Oct 31, 2022Common StockSSaleDisposed−5,008$44.93F6−$225,009.44117,992Indirect
Oct 31, 2022Common StockSSaleDisposed−4,569$46.19F7−$211,042.11113,423Indirect
Oct 31, 2022Common StockSSaleDisposed−8,235$46.91F8−$386,303.85105,188Indirect
Oct 31, 2022Common StockSSaleDisposed−2,188$47.91F9−$104,827.08103,000Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $44.48 to $45.445, inclusive.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $45.57 to $46.56, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.57 to $47.52, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.68 to $48.17, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $44.48 to $45.445, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $45.57 to $46.56, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.57 to $47.555, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.57 to $48.40, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)